Novartis | NOVN - Pasivo Circulante





Pasivo Circulante Cambio Fecha
AbbVie USD 42.1B 1.19B 2026-03
Alcon AG USD 3B 45M 2026-03
Almirall EUR 350.64M 52.12M 2025-12
Amgen USD 24.96B 534M 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
Autolus Therapeutics Ltd USD 63.6M 9.84M 2026-03
Bayer EUR 33.46B 875M 2026-03
Biogen USD 3B 350.5M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Eli Lilly USD 36.63B 1.41B 2026-03
Fresenius EUR 8.38B 1.18B 2025-12
Fresenius Medical Care EUR 6.73B 484.42M 2026-03
Genmab DKK 1.43B 686M 2025-12
Gilead Sciences USD 9.48B 2.34B 2026-03
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
GRIFOLS EUR 2.12B 105M 2026-03
Hikma Pharmaceutical USD 1.45B 603M 2025-12
J&J USD 57.72B 3.59B 2026-03
Lakefront Biotherapeutics EUR 100.42M 52.44M 2026-03
Lonza CHF 3.57B 421M 2025-12
Merck EUR 9.35B 307M 2026-03
Merck USD 26.94B 1.38B 2026-03
Novartis USD 31.37B 4.1B 2026-03
Novartis USD 27.28B 4.72B 2025-12
Novo Nordisk DKK 225.16B 9.5B 2026-03
Orion EUR 798.6M 238.3M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
Philips EUR 7.43B 78M 2026-03
Recordati EUR 1.37B 315.51M 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sanofi EUR 30.01B 1.66B 2026-03
UCB EUR 4.4B 470M 2025-12